Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels

Metabolic Syndrome Clinical Trial

Official title:

The Prevalence of Metabolic Syndrome in Patients With Psoriasis and Psoriatic Arthritis and Its Correlation With Disease Severity and Serum Omentin-1 and Visfatin Levels

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03932110
• Other study ID #: DDagdelen
• Status: Completed
• Phase: N/A
• Start date: April 15, 2019
• Est. completion date: June 14, 2019

Study information

• Verified date: June 2019
• Source: Istanbul Medeniyet University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. At the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by PASI psoriasis, clinical activity score for psoriatic arthritis). The patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. For the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: June 14, 2019
• Est. primary completion date: June 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic

2. Patients older than 18 years

3. Patients who accept dermatological and rheumatic examination

4. Patients not receiving systemic treatment related to the disease in the last 1 month

Exclusion Criteria:

1. Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis

2. Patients under 18 years

3. Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Metabolic Syndrome
• Psoriasis
• Psoriasis Vulgaris
• Psoriatic Arthritis
• Syndrome

Intervention

Diagnostic Test:
• omentin, visfatin
diagnostic blood test

Locations

Country	Name	City	State
Turkey	Istanbul Medeniyet University	Istanbul
Turkey	Istanbul Medeniyet University, Department of dermatology	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul Medeniyet University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	omentin	Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels	6 months
Primary	visfatin	Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue.	6 months